Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

In infants, especially with novel previously undescribed mutations of the KATP channel causing neonatal diabetes, in vitro studies can be used to both predict the response to sulphonylurea treatment and support a second trial of glibenclamide at higher than standard doses if the expected response is not observed.

Original publication

DOI

10.1002/ccr3.370

Type

Journal article

Journal

Clin Case Rep

Publication Date

10/2015

Volume

3

Pages

884 - 887

Keywords

Glibenclamide, K-ATP channel, in vitro, neonatal diabetes